IONIS PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on the 26 th day of February, 2026.
| IONIS PHARMACEUTICALS, INC. | |
| By: | /s/ BRETT P. MONIA |
| Brett P. Monia, Ph.D. | |
| Chief Executive Officer (Principal executive officer) |
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brett P. Monia and Elizabeth L. Hougen, or any of them, his or her attorney-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signatures | Title | Date |
|---|---|---|
| /s/ BRETT P. MONIA | Director and Chief Executive Officer | February 26, 2026 |
| Brett P. Monia, Ph.D. | (Principal executive officer) | |
| /s/ ELIZABETH L. HOUGEN | Executive Vice President, Finance and Chief Financial Officer | February 26, 2026 |
| Elizabeth L. Hougen | (Principal financial and accounting officer) | |
| /s/ JOSEPH LOSCALZO | Chairman of the Board | February 26, 2026 |
| Joseph Loscalzo, M.D., Ph.D. | ||
| /s/ SPENCER R. BERTHELSEN | Director | February 26, 2026 |
| Spencer R. Berthelsen, M.D. | ||
| /s/ ALLENE M. DIAZ | Director | February 26, 2026 |
| Allene M. Diaz | ||
| /s/ MICHAEL HAYDEN | Director | February 26, 2026 |
| Michael Hayden, CM OBC MB ChB PhD FRCP(C) FRSC | ||
| /s/ JOAN E. HERMAN | Director | February 26, 2026 |
| Joan E. Herman | ||
| /s/ JOSEPH KLEIN | Director | February 26, 2026 |
| Joseph Klein, III | ||
| /s/ B. LYNNE PARSHALL | Director | February 26, 2026 |
| B. Lynne Parshall, J.D. | ||
| /s/ JOSEPH H. WENDER | Director | February 26, 2026 |
| Joseph H. Wender | ||
| /s/ MICHAEL YANG | Director | February 26, 2026 |
| Michael Yang | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 42) | F-2 |
|---|---|
| Consolidated Balance Sheets at December 31, 2025 and 2024 | F-4 |
| Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 | F-5 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023 | F-6 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2025, 2024 and 2023 | F-7 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | F-8 |
| Notes to the Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.